QDII基金总规模年内增长26.5%

Group 1: QDII Fund Overview - As of September 12, the total number of QDII funds reached 314, with a total scale of 673 billion yuan, an increase of 141 billion yuan from the beginning of the year, representing a growth rate of 26.5% [1] - Among these, there are 215 equity QDII funds with a scale of 567.7 billion yuan, which accounts for the highest proportion in terms of both number and scale [1] - The significant growth in QDII fund scale this year reflects an increased demand for global asset allocation and improved risk tolerance among investors, influenced by the performance of certain QDII funds [1] Group 2: Performance of QDII Funds - The Hong Kong stock market has performed well this year, contributing to the strong performance of several QDII funds, with 25 funds showing a net value growth rate exceeding 80%, and some surpassing 100% [1] - Thematic funds focusing on innovative drugs and biotechnology have shown particularly strong performance [1] - Market experts attribute the strong performance of QDII funds to ample liquidity in the Hong Kong market and a robust valuation recovery, especially in sectors like innovative drugs, consumption, and technology [1] Group 3: Biopharmaceutical Industry Insights - The biopharmaceutical sector, including gene editing and synthetic biology, is recognized as a key driver for the development of new productive forces in China and is crucial for building a healthy China [2] - The long-term development of the biopharmaceutical industry is fundamentally driven by rigid demand, making it an attractive investment area for many investors [2] - Recent favorable policies in the domestic pharmaceutical industry support the development of innovative drugs across the entire chain, accelerating industry transformation [2]